In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.
Sant P. Chawla, MD
Advertisement
Articles by Sant P. Chawla, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
3
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC
4
IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer
5